Cantargia AB (SE:CANTA)
:CANTA
CANTA Stock Chart & Stats
kr4.17
-kr0.02(-1.25%)
At close: 4:00 PM EST
kr4.17
-kr0.02(-1.25%)
Day’s Range― - ―
52-Week Rangekr1.00 - kr6.59
Previous CloseN/A
Volume611.88K
Average Volume (3M)1.42M
Market Cap
kr1.02B
Enterprise Valuekr741.22M
Total Cash (Recent Filing)kr281.82M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.79
Next Earnings
May 26, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding248,611,650
10 Day Avg. Volume1,074,033
30 Day Avg. Volume1,417,172
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)3.91
Price to Sales (P/S)3.28
P/FCF Ratio6.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr13.95Price Target Upside234.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.63
Revenue Forecast (FY)kr2.93M
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentNadunolimab is positioned to enter a pivotal study alongside an IL1RAP-based companion diagnostic, which can improve patient selection and increase the chance of a clear clinical readout.
Indication Expansion And Combination PotentialAn investigator-initiated colorectal cancer study and data suggesting nadunolimab may prime tumors for checkpoint inhibitors expand its potential patient reach and collaboration opportunities.
Strategic PartnershipsThe CAN10 acquisition by a large pharmaceutical firm validated the IL1RAP approach and provided non-dilutive payments and royalties that free resources for advancing other pipeline programs.
Bears Say
Clinical Efficacy UncertaintyFailure to demonstrate meaningful immune priming or clinical effectiveness would limit nadunolimab's ability to compete with established checkpoint inhibitors and could hinder commercial prospects.
Patient Population ResistanceAnalyst cautions that the targeted colorectal cancer population has historically been non-responsive to immunotherapy, which raises the bar for demonstrating clinical benefit.
Regulatory And Financing RiskProgress toward a pivotal pancreatic cancer study depends on regulatory approval and securing financing, creating the risk of delays or altered trial plans.
Cantargia AB News
CANTA FAQ
What was Cantargia AB’s price range in the past 12 months?
Cantargia AB lowest stock price was kr1.00 and its highest was kr6.59 in the past 12 months.
What is Cantargia AB’s market cap?
Cantargia AB’s market cap is kr1.02B.
When is Cantargia AB’s upcoming earnings report date?
Cantargia AB’s upcoming earnings report date is May 26, 2026 which is in 60 days.
How were Cantargia AB’s earnings last quarter?
Cantargia AB released its earnings results on Feb 20, 2026. The company reported -kr0.13 earnings per share for the quarter, beating the consensus estimate of -kr0.19 by kr0.06.
Is Cantargia AB overvalued?
According to Wall Street analysts Cantargia AB’s price is currently Undervalued.
Does Cantargia AB pay dividends?
Cantargia AB does not currently pay dividends.
What is Cantargia AB’s EPS estimate?
Cantargia AB’s EPS estimate is -0.18.
How many shares outstanding does Cantargia AB have?
Cantargia AB has 248,611,650 shares outstanding.
What happened to Cantargia AB’s price movement after its last earnings report?
Cantargia AB reported an EPS of -kr0.13 in its last earnings report, beating expectations of -kr0.19. Following the earnings report the stock price went down -11.485%.
Which hedge fund is a major shareholder of Cantargia AB?
Currently, no hedge funds are holding shares in SE:CANTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cantargia AB
Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04, an antibody against Interleukin-1 Receptor Accessory Protein (IL1RAP) to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system and is under phase IIa clinical trial; and CAN10, an antibody against IL1RAP for treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis, and is under preclinical trial. It is also developing CANxx antibodies against IL1RAP. The company has collaboration agreements with Patheon Biologics BV and BioWa Inc. for the manufacture and production of CAN04; and Specialized Medical Services-oncology BV for the clinical study of CAN04. Cantargia AB (publ) was founded in 2010 and is based in Lund, Sweden.
CANTA Stock 12 Month Forecast
Average Price Target
kr13.95
▲(234.47% Upside)
Technical Analysis
Oncopeptides AB
―
SynAct Pharma AB
―
―
Guard Therapeutics International AB
―
Immunicum AB
―
Options Prices
Currently, No data available
---